Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
High-Risk Neuroblastoma Chemotherapy Without G-CSF
- Conditions
- Interventions
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT02786719
- Locations
- 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT02784054
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT02784015
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT02782754
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT02776605
- Locations
- 🇪🇸
Hospital Clinic, Barcelona, Spain
🇪🇸Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸Hospital 12 de Octubre, Madrid, Spain
Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)
- Conditions
- Interventions
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 11
- Registration Number
- NCT02773732
- Locations
- 🇺🇸
UF Health Shands Cancer Hospital, Gainesville, Florida, United States
Response-based Treatment of High-risk Neuroblastoma
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 54
- Registration Number
- NCT02771743
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- RTOG Foundation, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02768558
- Locations
- 🇺🇸
Virginia Mason, Seattle, Washington, United States
🇺🇸Mount Sinai Cancer Research Center, Miami Beach, Florida, United States
🇺🇸Reading Hospital/McGlinn Cancer Institute, West Reading, Pennsylvania, United States
A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
- Conditions
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 503
- Registration Number
- NCT02763579
- Locations
- 🇺🇸
Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States
🇺🇸Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas, Nevada, United States
🇺🇸Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States
Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- Giuseppe Giaccone
- Target Recruit Count
- 1
- Registration Number
- NCT02748889
- Locations
- 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.